PMID: 11607947Oct 19, 2001Paper

Discontinuation of lithium augmentation in an elderly cohort

International Journal of Geriatric Psychiatry
S Fahy, B A Lawlor

Abstract

To observe the effects of gradual discontinuation of lithium augmentation therapy in a group of patients over the age of 65 years and to measure the rate of relapse and to identify any factors which would predict relapse. This was a naturalistic study involving 21 patients who were on lithium augmentation and whose lithium was discontinued for a variety of clinical reasons. In most cases lithium was tapered and discontinued over a period of 2-12 weeks. Demographic and other variables were collected at baseline and compared between those who remained well and those that subsequently relapsed. Eleven patients (52.4%) relapsed following discontinuation of lithium augmentation. Those who relapsed had been on lithium for significantly longer than those who remained well off lithium (p = 0.007). There was a trend towards more hospital admissions in the relapse group (p = 0.062). When lithium augmentation therapy is discontinued in elderly depressives over half of these patients relapse. A longer duration of prediscontinuation lithium treatment and more hospital admissions appear to be associated with increased risk of relapse.

References

Jan 1, 1987·Progress in Neuro-psychopharmacology & Biological Psychiatry·K I ShulmanB Hardy
Mar 1, 1981·The British Journal of Psychiatry : the Journal of Mental Science·C Dé MontignyJ P Deschenes
Oct 1, 1994·Journal of Clinical Psychopharmacology·A J Flint, S L Rifat
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·C L KatonaM M Robertson
May 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·G Stein, M Bernadt
Mar 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H BendzM Aurell
Feb 1, 1997·Journal of Clinical Psychopharmacology·B G HardyC Zucchero
Jun 1, 1997·The Australian and New Zealand Journal of Psychiatry·I SchweitzerG Johnson
Aug 1, 1997·Clinical Neuropharmacology·B Kores, M H Lader
Aug 26, 1998·Journal of Affective Disorders·G Kirov
Nov 25, 1998·Thyroid : Official Journal of the American Thyroid Association·J H Lazarus
Apr 30, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Gitlin
Feb 15, 2000·The American Journal of Psychiatry·D A SolomonJ Endicott

❮ Previous
Next ❯

Citations

Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Mar 5, 2014·CNS Drugs·Michael BauerMaximilian Pilhatsch
Sep 19, 2007·Journal of Clinical Pharmacy and Therapeutics·A F CarvalhoM C O Lima
Feb 26, 2014·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Soham RejAndrea Gruneir
Apr 15, 2016·British Journal of Clinical Pharmacology·Amy T PageChristopher D Etherton-Beer
Apr 3, 2012·Journal of Geriatric Psychiatry and Neurology·Soham RejKenneth Shulman
Mar 25, 2008·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·James Ross
Sep 16, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Michael BauerTom Bschor
Mar 23, 2004·CNS Spectrums·Alastair J Flint
Jul 10, 2014·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Soham RejKarl Looper

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.